Search Results

You are looking at 131 - 140 of 152 items for :

  • Refine by Access: All x
Clear All
Full access

important in light of the COVID-19 pandemic, which has seen reduced screening numbers, which are projected to result in increased late-stage diagnoses. More on NCCN’s message that “Cancer Won’t Wait and Neither Should You” can be found at NCCN

Full access

Dingcheng Shen, Xiaolin Wang, Heng Wang, Gaopo Xu, Yumo Xie, Zhuokai Zhuang, Ziying Huang, Juan Li, Jinxin Lin, Puning Wang, Meijin Huang, Yanxin Luo, and Huichuan Yu

-specific mortality. It is well-known that elevated circulating CEA levels can also be found in some benign statuses and inflammation-derived diseases, such as COVID-19, 39 , 40 and the specificity of CEA for diagnosing primary gastrointestinal tumors is limited

Full access

comparable age, and 13% preferred someone of their own gender. One patient was unable to fill out baseline surveys due to worsening of their medical condition. Due to the COVID-19 pandemic, the trial was closed for the eight months but is now open to accrual

Full access

Alex J. Ball, Imran Aziz, Sophie Parker, Ravishankar B. Sargur, Jonathan Aldis, and Matthew Kurien

generated controversy and been used to mitigate pressure on endoscopic and radiologic resources, which have been impacted by the COVID-19 pandemic. 20 Future work needs to evaluate this evolving use of FIT to ensure appropriate triaging and prioritization

Full access

Lindsey Bandini, Alyssa Schatz, Victoria Hood, Nikia Clark, Michael J. Hall, and Robert W. Carlson

COVID-19 pandemic. Therefore, the timing is opportune to highlight recent successes across the field, while acknowledging where gaps still exist. Dr. Lisa Richardson, Director of the Division of Cancer Prevention and Control within the CDC, delivered a

Full access

.” The speakers offered many insights on leveraging technology to serve more patients. They acknowledged the massive expansion in telehealth was one positive thing to come from the COVID-19 pandemic. However, panel members pointed out that there is still

Full access

Presented by: Mazyar Shadman and Deborah M. Stephens

to flow cytometry for MRD testing,” he added. All 3 doctors agreed that the COVID-19 pandemic is shifting their thinking favoring small molecule inhibitors. “In this current situation we want to preserve immune function and try not to choose a therapy

Full access

Presented by: Chad A. LaGrange, M. Dror Michaelson, and Colleen H. Tetzlaff

of disease. The patient has no symptoms of disease, normal lab evaluations, and was working full-time until the COVID-19 pandemic. Case 2 was of a 51-year-old man with gross hematuria seen in September 2018. Initial management at that time was

Full access

Jennifer M. Snaman, Deborah Feifer, Gabrielle Helton, Yuchiao Chang, Areej El-Jawahri, Angelo E. Volandes, and Joanne Wolfe

allow for virtual enrollment and study completion due to the COVID-19 pandemic. After the initial mailed letter, eligible participants were called to provide further study details and assess interest. Members of the dyads completed study components on

Full access

Xudong Ni, Michael Luu, Weiwei Ma, Tingwei Zhang, Yu Wei, Stephen J. Freedland, Dingwei Ye, Timothy J. Daskivich, and Yao Zhu

patients during the COVID-19 pandemic . JAMA Oncol 2021 ; 7 : 1467 – 1473 . 34292311 8. Loeb S , Borno HT , Gomez S , Representation in online prostate cancer content lacks racial and ethnic diversity: implications for Black and